Why the study?
To examine the association between eGFR screening frequency and substantial eGFR reduction (≥ 25%) in type 2 diabetes patients with normal and impaired kidney function.
Does non-yearly eGFR screening compared to yearly screening increase the risk of substantial eGFR reduction in patients with type 2 diabetes?
Does non-yearly eGFR screening compared to yearly screening increase the risk of substantial eGFR reduction in patients with type 2 diabetes?
Non-yearly eGFR screening is associated with a higher risk of substantial renal function decline compared to yearly screening in type 2 diabetes patients with normal baseline kidney function.
Answers are grounded in this paper and cite their sources.
Yearly eGFR screening was associated with lower risk of substantial decline in preserved-function T2D; leaves open causality and optimal frequency.
Aims To examine the association of the screening frequency of estimated glomerular filtration rate (eGFR) with the substantial reduction in eGFR (≥ 25%) among type 2 diabetes (T2D) patients with normal (eGFR≥60 ml/min/1.73 m 2 ) and impaired kidney function (eGFR< 60 ml/min/1.73 m 2 ). Methods A longitudinal study involving 5104 T2D patients with follow-up period of 6.8 years (1.9 SD) were treated at the Rovaniemi Health Center, Rovaniemi, Finland during 2011–2019. The association between the screening frequency of eGFR (yearly vs. non-yearly) and the substantial reduction in eGFR was studied with logistical models and adjusted with biochemical variables and preventive medications. Results Among the T2D patients with normal kidney function, non-yearly eGFR screening was significantly associated with substantial eGFR reduction in both unadjusted (odds ratio [OR] 3.29, 95% confidence interval [CI] 2.54–4.33) and adjusted models (OR 2.06, 95% CI 1.21–3.73) compared with yearly screening frequency. In the group of patients with impaired kidney function in the unadjusted model, non-yearly eGFR screening was significantly associated with substantial eGFR reduction (OR 2.38, 95% CI 1.30–4.73), but became non-significant after adjustments (OR 1.89, 95% CI 0.61–7.21). Conclusions This study underscores the role of regular eGFR screening in the prevention of kidney function decline.
No takes yet. Share an insight, caveat, or question.
Sundqvist et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: